Sol Sherry, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
Though a safe and reliable form of thrombolytic therapy has not yet been established, progress continues in achieving this objective. Current interest centers about urokinase, a promising thrombolytic agent obtained from human urine. Since a major clinical trial to evaluate urokinase in the treatment of acute pulmonary embolism is scheduled to begin shortly, this presentation described the agent's development. The latter, requiring the close cooperation of the scientific community, the pharmaceutical industry, and the National Heart Institute, has resulted in  the production of preparations suitable for clinical investigation;  evidence that the intravenous administration of the agent produces a
Sherry S. The John Phillips Memorial Lecture: Urokinase.. Ann Intern Med. ;68:1139–1140. doi: 10.7326/0003-4819-68-5-1139_3
Download citation file:
Published: Ann Intern Med. 1968;68(5):1139-1140.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use